Patents by Inventor Bengt Guss
Bengt Guss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11981755Abstract: The present invention relates to novel compounds, which presents a peptide structure and an unexpected antibacterial effect even against certain multiresistant bacteria. The compounds may be cyclic peptides, sometimes depsipeptides, or non-ring-closed peptides, as defined by Formula (I). Further, the invention relates to the medical use of the herein claimed compounds, a method for the production of the compounds as well as a method of treatment including the compounds. In addition, the invention relates to a pharmaceutical preparation comprising one or more of the herein described and claimed compounds combined with suitable carrier(s) and/or adjuvant(s). Finally, the invention is the use of one or more of the claimed compounds in a method for decolonization of a surface of Gram-positive and/or Gram-negative bacteria.Type: GrantFiled: August 27, 2019Date of Patent: May 14, 2024Assignee: ULTUPHARMA ABInventors: Bo Öberg, Anders Broberg, Bengt Guss, Jolanta Levenfors, Joakim Bjerketorp, Christina Nord
-
Patent number: 11814415Abstract: The present disclosure relates to immunogenic polypeptides, immunogenic compositions and vaccine compositions and use thereof for immunization of mammals susceptible to Streptococcus suis infection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.Type: GrantFiled: October 22, 2021Date of Patent: November 14, 2023Assignee: INTERVACC ABInventors: Bengt Guss, Lars Frykberg, Margareta Flock, Jan-Ingmar Flock, Karl Olov Zachrisson
-
Publication number: 20220048957Abstract: The present disclosure relates to immunogenic polypeptides, immunogenic compositions and vaccine compositions and use thereof for immunization of mammals susceptible to Streptococcus suis infection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.Type: ApplicationFiled: October 22, 2021Publication date: February 17, 2022Inventors: Bengt GUSS, Lars FRYKBERG, Margareta FLOCK, Jan-Ingmar FLOCK, Karl Olov ZACHRISSON
-
Patent number: 11155585Abstract: The present disclosure relates to immunogenic polypeptides, immunogenic compositions and vaccine compositions and use thereof for immunization of mammals susceptible to Streptococcus suis infection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.Type: GrantFiled: July 8, 2016Date of Patent: October 26, 2021Assignee: INTERVACC ABInventors: Bengt Guss, Lars Frykberg, Margareta Flock, Jan-Ingmar Flock, Karl Olov Zachrisson
-
Publication number: 20210269483Abstract: The present invention relates to novel compounds, which presents a peptide structure and an unexpected antibacterial effect even against certain multiresistant bacteria. The compounds may becyclic peptides, sometimes depsipeptides, ornon-ring-closed peptides, asdefined by Formula (I). Further, the invention relates to the medical use of the herein claimed compounds, a method for the production of the compounds as well as a method of treatment including the compounds. In addition, the invention relates to a pharmaceutical preparation comprising one or more of the herein described and claimed compounds combined with suitable carrier(s) and/or adjuvant(s). Finally, the invention is the use of one or more of the claimed compounds in a method for decolonization of a surface of Gram-positive and/or Gram-negative bacteria.Type: ApplicationFiled: August 27, 2019Publication date: September 2, 2021Applicant: ULTUPHARMA ABInventors: Bo ÖBERG, Anders BROBERG, Bengt GUSS, Jolanta LEVENFORS, Joakim BJERKETORP, Christina NORD
-
Patent number: 10828317Abstract: The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be iclaprim; trimethoprim; or a compound comprising trimethoprim, such as trimethoprim-sulfa.Type: GrantFiled: May 24, 2018Date of Patent: November 10, 2020Assignee: Ultupharma ABInventors: Bo Öberg, Anders Broberg, Bengt Guss, Jolanta Levenfors, Joakim Bjerketorp, Christina Nord
-
Patent number: 10828316Abstract: The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be trimethoprim or a compound comprising trimethoprim, such as trimethoprim-sulfa.Type: GrantFiled: January 27, 2017Date of Patent: November 10, 2020Assignee: ULTUPHARMA ABInventors: Bo Öberg, Anders Broberg, Bengt Guss, Jolanta Levenfors, Joakim Bjerketorp, Christina Nord
-
Publication number: 20180325934Abstract: The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be trimethoprim or a compound comprising trimethoprim, such as trimethoprim-sulfa.Type: ApplicationFiled: January 27, 2017Publication date: November 15, 2018Applicant: ULTUPHARMA ABInventors: Bo ÖBERG, Anders BROBERG, Bengt GUSS, Jolanta LEVENFORS, Joakim BJERKETORP, Christina NORD
-
Publication number: 20180280417Abstract: The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be iclaprim; trimethoprim; or a compound comprising trimethoprim, such as trimethoprim-sulfa.Type: ApplicationFiled: May 24, 2018Publication date: October 4, 2018Applicant: ULTUPHARMA ABInventors: Bo ÖBERG, Anders BROBERG, Bengt GUSS, Jolanta LEVENFORS, Joakim BJERKETORP, Christina NORD
-
Publication number: 20180170974Abstract: The present disclosure relates to immunogenic polypeptides, immunogenic compositions and vaccine compositions and use thereof for immunization of mammals susceptible to Streptococcus suis infection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.Type: ApplicationFiled: July 8, 2016Publication date: June 21, 2018Inventors: Bengt GUSS, Lars FRYKBERG, Margareta FLOCK, Jan-Ingmar FLOCK, Karl Olov ZACHRISSON
-
Patent number: 9987342Abstract: The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. equi and subsp. zooepidemicus and use thereof for immunization of non-human mammals against S. equi subsp. equi and/or subsp. zooepidemicus. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component.Type: GrantFiled: May 13, 2013Date of Patent: June 5, 2018Assignee: INTERVACC ABInventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
-
Patent number: 9795664Abstract: An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein or polypeptide compromising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals against S. equi subsp. equi and/or subsp. zooepidemicus. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.Type: GrantFiled: December 4, 2015Date of Patent: October 24, 2017Assignee: Intervacc ABInventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
-
Patent number: 9333252Abstract: An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein or polypeptide comprising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals against S. equi subsp. equi and/or subsp. zooepidemicus. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.Type: GrantFiled: May 25, 2011Date of Patent: May 10, 2016Assignee: Intervacc ABInventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
-
Publication number: 20160082096Abstract: An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein or polypeptide compromising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals against S. equi subsp. equi and/or subsp. zooepidemicus. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.Type: ApplicationFiled: December 4, 2015Publication date: March 24, 2016Inventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
-
Publication number: 20140220064Abstract: The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. equi and subsp. zooepidemicus and use thereof for immunization of non-human mammals against S. equi subsp. equi and/or subsp. zooepidemicus. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component.Type: ApplicationFiled: May 13, 2013Publication date: August 7, 2014Inventors: Bengt GUSS, Jan-Ingmar FLOCK, Lars FRYKBERG, Margareta FLOCK
-
Publication number: 20130236469Abstract: An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein or polypeptide comprising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals against S. equi subsp. equi and/or subsp. zooepidemicus. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.Type: ApplicationFiled: May 25, 2011Publication date: September 12, 2013Applicant: Intervacc ABInventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
-
Patent number: 8404245Abstract: The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. Equi and subsp. Zooepidemicus and use thereof for immunization of non-human mammals against S. equi subsp. equi and/or subsp. Zooepidemicus. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component. The antigens used are EAG, FNZ, SFS, SEC and ScLC.Type: GrantFiled: October 10, 2003Date of Patent: March 26, 2013Assignee: Intervacc ABInventors: Bengt Guss, Jan-Ingmar Flock, Karin Jacobsson, Kenneth Janzon, Lars Frykberg, Margareta Flock, Rune Bergman
-
Publication number: 20120225079Abstract: An antigenic composition comprises at least one antigen, wherein said at least one antigen comprises at least part of a protein selected from EndoSe of Streptococcus equi subsp. Equi, EndoSz of Streptococcus equi subsp. zooepidemicus, and Endo S of Streptococcus pyogenes, and wherein said at least part of said protein comprises at least one antigenic epitope. A vaccine composition comprising the antigenic composition as immunizing component, methods for producing the antigeninc composition and the vaccine composition, use of the vaccine composition for prophylactic and therapeutic treatment, and an antibody preparation comprising monoclonal or polyclonal antibodies specific for an antigen or antigens of the antigenic composition are also disclosed.Type: ApplicationFiled: November 11, 2010Publication date: September 6, 2012Applicant: INTERVACC ABInventors: Bengt Guss, Lars Frykberg, Jan-Ingmar Flock, Margareta Flock
-
Publication number: 20110020403Abstract: The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. equi and subsp. zooepidemicus and use thereof for immunization of non-human mammals against S. equi subsp. equi and/or subsp. zooepidemicus. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component.Type: ApplicationFiled: December 12, 2008Publication date: January 27, 2011Inventors: Bengt Guss, Jan-Ingmar Flock, Lars Frykberg, Margareta Flock
-
Publication number: 20090214584Abstract: The present invention is directed toward isolated Staphylococcus epidermidis surface (Ses) A-F proteins, monoclonal and polyclonal antibodies directed against SesA-F proteins, vaccines comprising SesA-F proteins and diagnostic devices. The present invention is further directed to method of diagnosing an individual with Staphylococcus epidermidis comprising obtaining a sample from the individual and analyzing the sample for a Staphylococcus epidermidis surface (Ses) protein, wherein the Ses protein comprises SesA protein, SesB protein, SesC protein, SesD protein, SesE protein, SesF protein or a combination thereof.Type: ApplicationFiled: May 30, 2006Publication date: August 27, 2009Inventors: Bengt Guss, Jan Ingmar Flock